EVMN
Live News • Jul 01
Evommune Faces Investigation After Executives Sell Ahead of Failed Clinical Trial Announcement Levi & Korsinsky, LLP has begun an investigation into Evommune’s officers and directors after the CEO and CSO sold shares under Rule 10b5-1 plans shortly before disclosing that lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial. This announcement was followed by an approximate 38% share price drop.
The focus on insider stock sales ahead of negative clinical data raises potential securities law and governance concerns that could carry regulatory and reputational consequences for Evommune.
Evommune shares trade around $13.29, with the stock down about 45.2% over the past week.
This kind of legal scrutiny can add another layer of uncertainty on top of clinical risk. The key question is how any findings might affect Evommune’s leadership, costs and ability to fund future development work. Announcement • Jun 30
Evommune Reports Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Chronic Spontaneous Urticaria Evommune, Inc. announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The Phase 2b trial enrolled 160 moderate-to-severe antihistamine-refractory CSU patients in the United States, Europe, Canada and Japan. Participants received one of three active dose regimens or placebo. The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. EVO756 previously delivered positive Phase 2 data in chronic inducible urticaria and showed clear target engagement in the Phase 1 trial. Evommune is evaluating EVO756 in additional indications, and this Phase 2b trial confirmed safe and well tolerated doses that warrant these further studies. Evommune remains on track to report top-line Phase 2b data for EVO756 in atopic dermatitis (AD) in the third quarter of 2026. Screening has been initiated in a Phase 2b trial of EVO756 in migraine prophylaxis, and patient dosing is expected to commence imminently. For EVO301, Evommune recently reported positive Phase 2a proof-of-concept data in AD and plans to move the program into a robust Phase 2b AD trial. EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Evommune seeks to produce the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases, including atopic dermatitis (AD) and migraine, as well as additional possible indication expansions. EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. EVO301 facilitates more efficient tissue distribution and improved binding affinity and specificity relative to existing attempts to antagonize or inhibit the IL-18 pathway, including traditional mAbs. EVO301 incorporates several distinguishing design features, including selective and high binding affinity of native human IL-18BP and binding to serum albumin, smaller molecular weight, extended half-life for the neutralization of IL-18, and lower potential for immunogenicity. Evommune believes the distinct mechanism and modality of EVO301 complement those of EVO756, providing multiple, potentially synergistic avenues to bring innovative therapeutics to the large, underserved and rapidly expanding population of patients suffering from chronic inflammatory diseases. New Risk • Jun 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$176m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). 
